Surreal illustration of a hand with brachydactyly reaching towards a fragmented chromosome, representing BDMR.

Unlocking the Mystery of BDMR: When a Rare Syndrome Surfaces in Adulthood

Lena Voss in Health & Wellness October 2026 • 4 min read.

"Could your AHO-like symptoms actually be brachydactyly mental retardation syndrome? Learn to recognize the signs and the importance of early diagnosis."

Imagine navigating life with a condition that subtly alters your physical appearance and cognitive abilities, yet remains undiagnosed for decades. This is the reality for some individuals with brachydactyly mental retardation syndrome (BDMR), a rare genetic disorder caused by a small chromosomal deletion. BDMR often presents with a complex array of symptoms that can mimic other, more common conditions, leading to delayed or incorrect diagnoses.

One such condition is Albright hereditary osteodystrophy (AHO), a genetic disorder affecting hormone resistance and skeletal development. Because BDMR can share similar skeletal and craniofacial features with AHO, it's not uncommon for individuals to be misdiagnosed. However, BDMR is a distinct condition with its own set of potential health challenges, making accurate diagnosis crucial for appropriate management and care.

This article delves into a fascinating case study of BDMR diagnosed in adulthood, highlighting the diagnostic challenges and the importance of considering BDMR in individuals who present with AHO-like symptoms but have normal calcium metabolism. We'll explore the key characteristics of BDMR, its potential complications, and the steps healthcare professionals can take to ensure accurate and timely diagnoses.

AI Search Multiple angles on this topic

Stats & Impact

BDMR: A Rare Genetic Condition

Brachydactyly mental retardation syndrome (BDMR) is a rare congenital condition caused by deletion of chromosome 2q37, with roughly 100 cases reported worldwide. The syndrome presents with a range of features including short stature, brachydactyly type E, obesity, a round face, congenital heart defects, autism spectrum disorder, and mild-to-moderate intellectual disability. BDMR has been confirmed to be associated with deletions of the 2q37 chromosomal region, making it a genetically defined disorder with variable clinical expression. Its rarity means that many clinicians may never encounter a case during their careers.

Standard Approach

Diagnosis and Diagnostic Challenges

Diagnosis of BDMR relies on genetic testing to detect deletions or mutations in the 2q37 region, particularly involving the HDAC4 gene. Williams et al. (2010) identified both chromosomal deletions and point mutations in HDAC4 among patients with the syndrome, establishing the gene's central role. A significant diagnostic challenge is that BDMR can be misdiagnosed as Albright hereditary osteodystrophy (AHO) due to overlapping skeletal and craniofacial features. However, unlike AHO, BDMR patients lack hormone resistance and maintain normal calcium metabolism, making biochemical markers essential for distinguishing between the two conditions.

History

Early Understanding of BDMR

The characterization of BDMR as a distinct clinical entity emerged as genetic mapping techniques advanced in the late 20th and early 21st centuries. Early recognition of the syndrome relied heavily on identifying the constellation of brachydactyly and intellectual disability, though it was not until chromosomal analysis became routine that the underlying 2q37 deletion was implicated. Over time, the identification of HDAC4 as a key gene in the disorder's pathogenesis marked an important milestone in understanding the molecular basis of BDMR. As with many rare genetic conditions, the historical trajectory of BDMR research has been shaped by gradual accumulation of case reports rather than large-scale studies.

Main

End

BDMR vs. AHO: Spotting the Subtle Differences

Surreal illustration of a hand with brachydactyly reaching towards a fragmented chromosome, representing BDMR.

Brachydactyly mental retardation syndrome (BDMR), also known as 2q37 deletion syndrome, is a rare genetic disorder affecting approximately 1 in 1 million individuals. It arises from a deletion on the long arm (q arm) of chromosome 2, specifically at the 2q37 locus. The size of the deletion can vary, leading to a wide range of symptoms and severity among affected individuals.

One of the main reasons BDMR can be mistaken for Albright hereditary osteodystrophy (AHO) is the presence of similar physical features. Both conditions can cause:

Short stature
Round face
Skeletal abnormalities (particularly affecting the hands and feet)
Mild intellectual disability

However, a key difference lies in hormone resistance. AHO is characterized by resistance to parathyroid hormone (PTH), which regulates calcium levels in the blood. This resistance leads to low calcium and high phosphate levels. In contrast, individuals with BDMR typically have normal hormone levels and calcium metabolism, making standard AHO blood tests unreliable for diagnosis.

The Road to Accurate Diagnosis: What to Do Next

While BDMR remains a rare and complex condition, increased awareness and understanding are crucial for improving diagnostic accuracy and patient care. If you or someone you know exhibits AHO-like symptoms but has normal calcium levels, it’s important to consider BDMR as a possibility. Talk to your doctor about genetic testing, which can confirm or rule out the 2q37 deletion. Early diagnosis can help manage potential complications, provide access to supportive therapies, and connect you with resources and support networks.

What the HDAC4 variant evidence can show

The proposed effect of the HDAC4 variant is not experimentally established: functional analyses were not performed, so the account presents a possible explanation rather than a demonstrated mechanism.^[1]

The authors also state that they cannot attribute the family’s symptoms to that variant without functional analysis. This keeps the genetic finding distinct from proof of cause.^[1]

What remains unresolved about BDMR biology

How does reduced HDAC4 function lead to skeletal features such as brachydactyly, short stature, and facial differences? The mechanism remains unknown.^[1]
Would functional testing show that the p.Arg735Gln variant changes HDAC4 activity in a way that produces the family’s symptoms? The reported work did not perform that analysis.^[1]

Questions about the candidate genes

What gene was proposed as a candidate for brachydactyly type E?

Syrrou and colleagues proposed Glypican1, which is involved in neural and skeletal development, as a candidate for brachydactyly type E, a phenotype marked by shortened metacarpals.^[2]

Sources

A family with brachydactyly mental retardation syndrome with a missense variant in HDAC4 (pmc.ncbi.nlm.nih.gov)
Brachydactyly Mental Retardation Syndrome Diagnosed in Adulthood (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

What is Brachydactyly Mental Retardation Syndrome (BDMR), and why is it sometimes mistaken for other conditions?

Brachydactyly Mental Retardation Syndrome (BDMR), also known as 2q37 deletion syndrome, is a rare genetic disorder resulting from a deletion on the long arm of chromosome 2 at the 2q37 locus. It's often mistaken for conditions like Albright hereditary osteodystrophy (AHO) because both can present with similar features, such as short stature, a round face, skeletal abnormalities, and mild intellectual disability. The similarity in physical traits can lead to initial misdiagnosis.

How does BDMR differ from Albright hereditary osteodystrophy (AHO) in terms of hormone resistance and calcium metabolism?

The key difference between BDMR and Albright hereditary osteodystrophy (AHO) lies in hormone resistance. AHO is characterized by resistance to parathyroid hormone (PTH), leading to low calcium and high phosphate levels in the blood. In contrast, individuals with BDMR typically have normal hormone levels and calcium metabolism. This means that standard blood tests used to diagnose AHO are often unreliable for diagnosing BDMR.

If someone exhibits AHO-like symptoms but has normal calcium levels, what steps should they take to explore a possible BDMR diagnosis?

If an individual presents with Albright hereditary osteodystrophy (AHO)-like symptoms but has normal calcium levels, it's crucial to consider Brachydactyly Mental Retardation Syndrome (BDMR) as a possibility. The next step is to consult with a healthcare professional about genetic testing, which can confirm or rule out the 2q37 deletion associated with BDMR. Early diagnosis through genetic testing is essential for appropriate management and access to supportive therapies.

What are the potential complications associated with Brachydactyly Mental Retardation Syndrome (BDMR), and how can early diagnosis help in managing them?

While the specific complications associated with Brachydactyly Mental Retardation Syndrome (BDMR) are not detailed, early diagnosis enables proactive management. Although not explicitly mentioned, these complications could potentially involve developmental delays, behavioral issues, or specific organ system abnormalities. Early diagnosis facilitates access to supportive therapies like speech, occupational, and physical therapy, along with behavioral interventions, potentially mitigating the impact of these complications. Furthermore, a confirmed diagnosis allows families to connect with specialized resources and support networks to better navigate the challenges associated with BDMR.

Given that the size of the 2q37 deletion varies in individuals with BDMR, how does this impact the range and severity of symptoms experienced?

The size of the deletion on the long arm of chromosome 2 (2q37) in Brachydactyly Mental Retardation Syndrome (BDMR) varies among affected individuals, leading to a wide range of symptoms and severity. Larger deletions may result in a more pronounced presentation of the syndrome, potentially involving more significant intellectual disability, more severe skeletal abnormalities, or a broader spectrum of associated health issues. Conversely, smaller deletions might lead to milder symptoms, making diagnosis more challenging. Further research correlating deletion size with specific clinical manifestations is needed to fully understand the genotype-phenotype relationship in BDMR.